2024
Reporting checklists in neuroimaging: promoting transparency, replicability, and reproducibility
Ekhtiari H, Zare-Bidoky M, Sangchooli A, Valyan A, Abi-Dargham A, Cannon D, Carter C, Garavan H, George T, Ghobadi-Azbari P, Juchem C, Krystal J, Nichols T, Öngür D, Pernet C, Poldrack R, Thompson P, Paulus M. Reporting checklists in neuroimaging: promoting transparency, replicability, and reproducibility. Neuropsychopharmacology 2024, 50: 67-84. PMID: 39242922, PMCID: PMC11525976, DOI: 10.1038/s41386-024-01973-5.Peer-Reviewed Original Research
1995
Effects of the benzodiazepine antagonist flumazenil in PTSD
Randall P, Bremner J, Krystal J, Nagy L, Heninger G, Nicolaou A, Charney D. Effects of the benzodiazepine antagonist flumazenil in PTSD. Biological Psychiatry 1995, 38: 319-324. PMID: 7495926, DOI: 10.1016/0006-3223(94)00306-n.Peer-Reviewed Original ResearchConceptsVisual analogue rating scaleAdministration of flumazenilAnxiety symptomsCrossover study designBenzodiazepine antagonist flumazenilGABAA receptor complexBenzodiazepine/GABAA receptor complexPanic disorder patientsAnalogue rating scalesFlumazenil administrationPTSD Symptom ScaleIntravenous infusionAntagonist flumazenilGABAA antagonistHealthy controlsClinical studiesDisorder patientsSymptom ScaleFlumazenilPanic disorderPanic attacksVietnam combat veteransStudy designRating ScalePTSD symptoms